Skip to main content

Advertisement

SpringerLink
Log in

RETRACTED ARTICLE: Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?

  • Original Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

This article was retracted on 04 February 2014

Abstract

The purpose of this study is to find out the frequency of TP53 mutations in acute myeloid leukemia (AML) patients and correlate sensitivity of drug response with TP53 mutations. In AML more than 90 % of cases comprise of wild type TP53. 94.2 % of TP53 mutations are found within exon 5–8 of which 73 % are point mutations. TP53 mutations were analysed with high resolution melting curve analysis. We analysed 106 AML samples of which we found nine mutations which represents 8.5 % mutation rate and found one rare SNP. The effect of TP53 mutations were studied on the chemosensitivity of two new drugs AZD115 and RHPS4, an Aurora Kinase B inhibitor and Telomerase inhibitor respectively. Four mutations were found out of 17 for RHPS4 stating significant (p = 0.002) increase in sensitivity and no mutation found in AZD1152 database, but need more study to get definite conclusion.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Iwakuma T, Adhikari AS. Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications. Fukuoka Acta Med. 2009;100(6):217–28.

    PubMed  Google Scholar 

  2. Stojnev Slavica, Golubović Mlađan, Babović Petar. TP53 gene mutations—from guardian of the genome to oncogene. Acta Medica Medianae. 2010;49(1):59–63.

    Google Scholar 

  3. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60(24):6788–93.

    CAS  PubMed  Google Scholar 

  4. Krypuy M, et al. High resolution melting for mutation scanning of TP53 exons 5–8. BMC cancer. 2007;7:168.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology. 2009;2009(1):385–95.

    Article  Google Scholar 

  6. Ånensen N. p53 protein biosignatures in acute myeloid leukemia. Bergen: The University of Bergen; 2006.

    Google Scholar 

  7. Tao Y, et al. The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle. 2009;8(19):3172–81.

    Article  CAS  PubMed  Google Scholar 

  8. Ikezoe T, et al. p53 is critical for the aurora B kinase inhibitor-mediated apoptosis in acute myelogenous leukemia cells. Int J Hematol. 2010;91(1):69–77.

    Article  CAS  PubMed  Google Scholar 

  9. Grundy M, et al. The FLT3 internal tandem duplication mutation is a secondary target of the aurora B Kinase inhibitor AZD1152-HQPA in acute myelogenous leukemia cells. Mol Cancer Ther. 2010;9(3):661–72.

    Article  CAS  PubMed  Google Scholar 

  10. Curry J, et al. Aurora B kinase inhibition in mitosis: strategies for optimizing the use of aurora kinase inhibitors such as AT9283. Cell Cycle. 2009;8(12):1921–9.

    Article  CAS  PubMed  Google Scholar 

  11. Yang J, et al. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo. Blood. 2007;110(6):2034–40.

    Article  CAS  PubMed  Google Scholar 

  12. Rizzo Angela, et al. Stabilization of quadruplex DNA perturbs telomere replication leading to the activation of an ATR-dependent ATM signaling pathway. Nucl Acid Res. 2009;37:5353–64.

    Article  CAS  Google Scholar 

  13. Salvati E, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Investig. 2007;117(11):3236–47.

    Article  CAS  PubMed  Google Scholar 

  14. Biroccio A, et al. TRF2 inhibition triggers apoptosis and reduces tumorigenicity of human melanoma cells. Eur J Cancer. 2006;42:1881–8.

    Article  CAS  PubMed  Google Scholar 

  15. Forbes S, et al. Cosmic 2005. Br J Cancer. 2006;94(2):318–22.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Sugimoto K, et al. Frequent mutations in the P53 gene in human myeloid-leukemia cell-lines. Blood. 1992;79(9):2378–83.

    CAS  PubMed  Google Scholar 

  17. Farrell PJ, et al. p53 is frequently mutated in Burkitt’s lymphoma cell lines. EMBO J. 1991;10(10):2879–87.

    CAS  PubMed  Google Scholar 

  18. Gaidano G, et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Nat Acad Sci USA. 1991;88(12):5413–7.

    Article  CAS  PubMed  Google Scholar 

  19. Nigro JM, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342(6250):705–8.

    Article  CAS  PubMed  Google Scholar 

  20. Neubauer A, He M, Schmidt CA, et al. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia. 1993;7:593–600.

    CAS  PubMed  Google Scholar 

  21. Ogino S, et al. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn. 2005;7(3):413–21.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Liew M, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004;50(7):1156–64.

    Article  CAS  PubMed  Google Scholar 

  23. Garritano S, et al. Determining the effectiveness of high resolution melting analysis for SNP genotyping and mutation scanning at the TP53 locus. BMC Genet. 2009;10(1):5.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Gonzalez-Bosquet J, et al. Detection of somatic mutations by high-resolution DNA Melting (HRM) analysis in multiple cancers. PLoS ONE. 2011;6(1):e14522.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Krypuy M, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC cancer. 2006;6(1):295.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Liew M, et al. Genotyping of single-nucleotide polymorphisms by high-resolution melting of small amplicons. Clin Chem. 2004;50(7):1156–64.

    Article  CAS  PubMed  Google Scholar 

  27. Reed GH, Wittwer CT. Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem. 2004;50(10):1748–54.

    Article  CAS  PubMed  Google Scholar 

  28. Haferlach C, et al. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22(8):1539–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

I thank my supervisor Dr Claire Seedhouse (Haematology department, city hospital) for support and help during the entire project and Martin Grundy for providing drug database. I am obliged to all my colleagues and my family who supported me to accomplish my project successfully.

Author information

Authors and Affiliations

  1. Department of Molecular Medical Sciences, Queens Medical Centre, University of Nottingham, Nottingham, NG7 2UH, UK

    Ankur Shah

  2. Department of Academic Haematology, University of Nottingham, Nottingham, UK

    Claire Seedhouse

Authors
  1. Ankur Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claire Seedhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ankur Shah.

Additional information

This article has been retracted at the request of the second author of the paper, Claire Seedhouse, whose name was included in the paper without her permission. Further, the data in the paper has been published without any approvals from the department or the institution, where the corresponding author, Ankur Shah, was working at the time of submitting this paper.

An erratum to this article is available at http://dx.doi.org/10.1007/s12291-014-0422-8.

About this article

Cite this article

Shah, A., Seedhouse, C. RETRACTED ARTICLE: Frequency of TP53 Mutations and its Impact on Drug Sensitivity in Acute Myeloid Leukemia?. Ind J Clin Biochem 27, 121–126 (2012). https://doi.org/10.1007/s12291-012-0203-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-012-0203-1

Keywords

Search

Navigation